Bone strength and surrogate markers: The first, second, and third fiddle

Journal of Bone and Mineral Research

Volumn 27, Issue 8, 2012, Pages 1623-1626

  Miller, Paul D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

BONE DENSITY; BONE STRENGTH; BONE TURNOVER; DISEASE MARKER; DRUG EFFECT; DRUG POTENCY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; NOTE; PATIENT COMPLIANCE; RISK REDUCTION;

BONE DENSITY; DIPHOSPHONATES; FEMALE; HIP; HUMANS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

EID: 84864133908     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1673     Document Type: Note

References (47)

1. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 3rd., Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990; 322 (12): 802-9.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE,. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535-41.
3. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ,. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000; 12: 1-12.
4. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R,. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002; 71: 103-11.
5. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker R,. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008; 35: 488-97.
6. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu HL, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR,. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356 (18): 1809-22.
7. Wasnich RD, Miller PD,. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000; 85: 1-6.
8. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM,. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112: 281-9.
9. Delmas PD, Li Z, Cooper C,. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. 2004; 19: 330-7.
10. Delmas PD, Seeman E,. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone. 2004; 34: 599-604.
11. Rosen CJ, Hochberg M, Bonnick S, McClung MR, Miller PD, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE,. Fosamax-Actonel Comparator Trial Investigators. Treatment with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized, double-blind study. J Bone Miner Res. 2005; 20: 141-51.
12. Miller PD, Epstein S, Sedarati F, Reginster JY,. Once monthly oral ibandronate compared with weekly alendronate: results from the head-to-head MOTION study. Curr Med Res Opin. 2008; 24: 207-13.
13. Li Z, Meredith MP, Hoseyni MS,. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001; 20: 3175-88.
14. Shih J, Bauer DC, Orloff J, Capizzi T, Thompson D, Oppenheimer L, Ross PD,. Proportion of fracture risk reduction explained by BMD changes using Freedman analysis depends on choice of predictors. Osteoporos Int. 2002; 13 (Suppl): S38-9.
15. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD,. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002; 17: 1-10.
16. Miller PD, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR,. Increases in hip and spine bone mineral density are predictive for vertebral anti-fracture efficacy with ibandronate. Calcif Tissue Int. 2010; 87 (4): 305-13.
17. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH,. Change in lumbar spine bone mineral density and vertebral fracture risk reduction in teraparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 1785-90.
18. Watts NB, Miller PD, Kohlmeier LA, Sebba A, Chen P, Wong M, Krohn K,. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. J Bone Miner Res. 2009; 24 (6): 1125-31.
19. Hochberg M, Greenspan S, Wasnich R, Miller PD, Thompson D, Ross P,. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002; 87: 1586-92.
20. Watts NB, Geusens P, Barton IP, Felsenberg D,. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005; 20: 2097-104.
21. Miller PD,. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Curr Med Res Opin. 2008; 24: 107-19.
22. Bonnick SL, Lee Shulman L,. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006; 119 (4A): 25-31.
23. Griffith JF, Engelke K, Genant HK,. Looking beyond bone mineral density: Imaging assessment of bone quality. Ann N Y Acad Sci. 2010; 1192: 45-56. Review.
24. Amin S, Kopperdhal DL, Melton LJ 3rd, Achenbach SJ, Therneau TM, Riggs BL, Keaveny TM, Khosla S,. Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res. 2011; 26 (7): 1593-600.
25. Keaveny TM,. Biomechanical computed tomography-noninvasive bone strength analysis using clinical computed tomography scans. Ann NY Acad Sci. 2010; 1192: 57-65.
26. Lundy MW, Stauffer M, Wergedal JE, Baylink DJ, Featherstone JD, Hodgson SF, Riggs BL,. Histomorphometric analysis of iliac crest biopsies in placebo treated vs fluoride treated subjects. Osteoporos Int. 1995; 5 (2): 115-29.
27. Lewiecki EM, Watts NB,. Assessing response to osteoporosis therapy. Osteoporos Int. 2008; 19 (10): 1363-8.
28. Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Geusens PP, Miller PD, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP,. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009; 24 (10): 1643-6.
29. Miller PD, Zapalowski C, Kulak CAM, Bilezikian JP,. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab. 1999; 84: 1867-71.
30. Hernandez CJ,. How can bone turnover modify bone strength independent of bone mass?. Bone. 2008; 42: 1014-20.
31. Civitelli R, Armamento-Villareal R, Napoli N,. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009; 20: 843-51.
32. Eastell R, Hannon RA,. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc. 2008; 67: 157-62.
33. McCloskey EV, Vasikaran S, Cooper C,. FRAX(®) Position Development Conference Members. Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom. 2011; 14 (3): 220-2.
34. Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC,. Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int. 2010; 21: 439-45.
35. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung MR, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA;, for the IOF-IFCC Bone Marker Standard Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011; 22: 391-420.
36. Bauer DC, Leary E, Silverman S, Lane N, Payette M, Krege J, Libanati C, Miller PD, Durham S, Myers G, Vesper HE, Randall S, Lee D, Lindsay R,. National Bone Health Alliance Bone Marker Turnover Project: Current practices and the need for U.S. harmonization, standardization and common reference ranges. Osteoporosis Int. 2012; in press.
37. Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R,. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012; 27: 1627-1634.
38. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR;, FREEDOM Trial. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012; 27 (3): 687-93.
39. Cohen A, Dempster DW, Recker RR, Stein EM, Lappe JM, Zhou H, Wirth AJ, van Lenthe GH, Kohler T, Zwahlen A, Müller R, Rosen CJ, Cremers S, Nickolas TL, McMahon DJ, Rogers H, Staron RB, LeMaster J, Shane E,. Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab. 2011; 96 (10): 3095-105.
40. Siegmund T, Allen MR, Burr DB,. Can deterministic mechanical size effects contribute to fracture and microdamage accumulation in trabecular bone?. J Theor Biol. 2010; 265 (2): 202-10.
41. Eswaran SK, Bevill G, Nagarathnam P, Allen MR, Burr DB, Keaveny TM,. Effects of suppression of bone turnover on cortical and trabecular load sharing in the canine vertebral body. J Biomech. 2009; 11; 42 (4): 517-23.
42. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT,. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006; 39 (2): 345-52.
43. Christiansen BA, Kopperdahl DL, Kiel DP, Keaveny TM, Bouxsein ML,. Mechanical contributions of the cortical and trabecular compartments contribute to differences in age-related changes in vertebral body strength in men and women assessed by QCT-based finite element analysis. J Bone Miner Res. 2011; 26 (5): 974-83. DOI: 10.1002/jbmr.287.
44. Lewiecki EM, Laster AJ, Miller PD, Bilezikian JP,. More bone testing is needed, not less. J Bone Miner Res. 2012; 27 (4): 739-42.
45. Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E,. Importance of precision in bone density measurements. J Clin Densitom. 2001; 4 (2): 105-10.
46. Leslie WD, Moayyeri A;, Manitoba Bone Density Program. Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring. Osteoporos Int. 2006; 17 (11): 1673-80.
47. Lewiecki EM, Binkley N, Petak SM,. DXA quality matters. J Clin Densitom. 2006; 9 (4): 388-92.